PMID- 20166207
OWN - NLM
STAT- MEDLINE
DCOM- 20100506
LR  - 20220316
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 116
IP  - 8
DP  - 2010 Apr 15
TI  - Circulating endothelial cells in patients with chronic lymphocytic leukemia: 
      clinical-prognostic and biologic significance.
PG  - 1926-37
LID - 10.1002/cncr.24961 [doi]
AB  - BACKGROUND: In patients with cancer, circulating endothelial cells (CECs) are 
      increased and are correlated with an aggressive disease course. However, the 
      clinical and biologic significance of CECs in chronic lymphocytic leukemia (CLL) 
      remains uncertain. METHODS: In 170 patients with CLL, CEC levels were quantified 
      by flow cytometry and were correlated with clinical and biologic data. In 
      addition, CECs were characterized by immunophenotypic, fluorescence in situ 
      hybridization (FISH), and gene expression profile analyses. RESULTS: In patients 
      with CLL, CECs were increased compared with controls. A higher level of CECs 
      (>20/microL) identified a subset of patients with a more aggressive disease 
      course characterized by a shorter time to first treatment both in univariate and 
      multivariate analyses. In FISH analysis, 7 patients had a significant proportion 
      of CECs and presented with the same cytogenetic lesion of neoplastic lymphocytes 
      and immunophenotypic features of endothelial progenitor cells. The gene 
      expression profile of sorted CECs revealed a molecular pattern, suggesting a 
      derivation from CLL leukemic cells with increased cell survival and 
      proliferation, diminished cell adhesion to extracellular matrix, and enhanced 
      proangiogenic function compared with their normal counterparts. CONCLUSIONS: The 
      current data suggest that, in CLL, CECs may represent a biologic marker of 
      aggressiveness and disease progression to be considered for new, targeted 
      antiangiogenic treatments.
CI  - (c) 2010 American Cancer Society.
FAU - Rigolin, Gian Matteo
AU  - Rigolin GM
AD  - Hematology Section, St. Anna University Hospital, University of Ferrara, Ferrara, 
      Italy. rglgmt@unife.it
FAU - Maffei, Rossana
AU  - Maffei R
FAU - Rizzotto, Lara
AU  - Rizzotto L
FAU - Ciccone, Maria
AU  - Ciccone M
FAU - Sofritti, Olga
AU  - Sofritti O
FAU - Daghia, Giulia
AU  - Daghia G
FAU - Cibien, Francesca
AU  - Cibien F
FAU - Cavazzini, Francesco
AU  - Cavazzini F
FAU - Marasca, Roberto
AU  - Marasca R
FAU - Cuneo, Antonio
AU  - Cuneo A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antigens, CD19)
SB  - IM
EIN - Cancer. 2010 Jun 1;116(11):2726
MH  - Aged
MH  - Antigens, CD19/metabolism
MH  - Chromosome Aberrations
MH  - Endothelial Cells/metabolism/*pathology
MH  - Female
MH  - Flow Cytometry
MH  - Gene Expression Profiling
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neovascularization, Pathologic/pathology
MH  - Prognosis
EDAT- 2010/02/19 06:00
MHDA- 2010/05/07 06:00
CRDT- 2010/02/19 06:00
PHST- 2010/02/19 06:00 [entrez]
PHST- 2010/02/19 06:00 [pubmed]
PHST- 2010/05/07 06:00 [medline]
AID - 10.1002/cncr.24961 [doi]
PST - ppublish
SO  - Cancer. 2010 Apr 15;116(8):1926-37. doi: 10.1002/cncr.24961.